Literature DB >> 12396415

Improving drug delivery from medical nebulizers: the effects of increased nebulizer flow rates and reservoirs.

T E Corcoran1, J H Dauber, N Chigier, A T Iacono.   

Abstract

Drug delivery from jet nebulizers can be considered in terms of the dose inhaled and the respirability of that dose. It is proposed that dose respirability and dose per breath can be controlled through specification of the driving gas flowrate, and that the dose inhaled per breath can also be increased through the use of nebulizer reservoirs. When a Hudson Micromist nebulizer was used and assessments of respirability were made utilizing phase Doppler interferometry, it was noted that the portion of the spray mass in droplet sizes of <or=5 microm (general respirability) and in droplet sizes of <or=3 microm (deep lung respirability) increased linearly with gas flowrate for both tank air and helium-oxygen (70/30). Drug mass in the 2-6 microm range (tracheobronchial respirability) peaked at air flowrates of 8-10 LPM and decreased slightly for higher flowrates. Two portable compressors provided respirabilities similar to tank air at the same flowrates. Changing the nebulizer flowrate did not affect the ratio of the inhaled dose to the dose expelled by exhalation when a typical breathing pattern was simulated. A version of the Micromist with an attached reservoir (the Hudson AeroTee) provided a higher dose per breath to the patient and a higher total dose for the same treatment time by conserving the aerosol generated during exhalation. The inhaled dose increased approximately 28% when compared to a standard Micromist, despite significant deposition in the reservoir bag. Nebulizer reservoirs could be used to attain higher doses or to more efficiently utilize expensive medications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12396415     DOI: 10.1089/089426802760292618

Source DB:  PubMed          Journal:  J Aerosol Med        ISSN: 0894-2684


  2 in total

1.  Regional Ventilation and Aerosol Deposition with Helium-Oxygen in Bronchoconstricted Asthmatic Lungs.

Authors:  Elliot Eliyahu Greenblatt; Tilo Winkler; Robert Scott Harris; Vanessa Jane Kelly; Mamary Kone; Ira Katz; Andrew Martin; George Caillibotte; Dean R Hess; Jose G Venegas
Journal:  J Aerosol Med Pulm Drug Deliv       Date:  2016-01-29       Impact factor: 2.849

2.  Treatment of asthma exacerbations with the human-powered nebuliser: a randomised parallel-group clinical trial.

Authors:  Christopher J Hallberg; M Therese Lysaught; René Antonio Najarro; Fausto Cea Gil; Clara Villatoro; Ana Celia Diaz de Uriarte; Lars E Olson
Journal:  NPJ Prim Care Respir Med       Date:  2014-06-26       Impact factor: 2.871

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.